Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... ViroScore Suite™ and other online services primarily in the field of HIV/AIDS and viral hepatitis. Through the agreement, Centro de Genomas will provide the advanced ...
2009 NOV 23 ... a medical device being advanced as an adjunct therapy for Hepatitis-C (HCV) and other viral pathogens, is capable of capturing exosomes secreted by solid tumors, lymphomas, and ...
2009 NOV 23 ... Center Diseases Control & Prevention, Division TB Eliminat, National Center HIV AIDS Viral Hepatitis Sexually Transm, 1600 Clifton Rd., Mailstop E-10, Atlanta, GA 30333, USA. ...
2009 NOV 23 ... need here in the United States and around the world, particularly to address key viral infections, including infections from the influenza viruses and human immunodeficiency ... to develop novel adjuvants to support the development of an effective vaccine against hepatitis C virus." Dr. Gale's laboratory has been instrumental in defining the ...
2009 NOV 23 ... Histology, Infectious Disease, Oncology, VEGF, Vascular Endothelial Growth Factor, Viral, Virology, University of Zagreb. This article was prepared by Clinical ... while in dogs the tissue adjacent to tumor was not changed. In humans in two cases hepatitis B virus (HBV) and in one case hepatitis C virus (HCV) were determined. Investigation ...
2009 NOV 23 ... Hepatitis, Infectious Disease, SARS, Severe Acute Respiratory Syndrome, Treatment, Viral Inhibition, Viral Therapy, Virology. This article was prepared by Biotech ...
2009 NOV 23 ... of marketed vaccine products in China and R&D projects focused on various preventable viral and bacterial diseases. Tianyuan has been delivering dynamic and profitable growth, ... repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatitis C and HIV. To receive future updates, via email including quarterly ...
2009 NOV 23 ... the new issue of the Journal of the American Medical Association, "Silent Epidemic of Viral Hepatitis May Lead to Boom in Serious Liver Disease," underscores the urgent need for Congress to ...
2009 NOV 23 ... or lamivudine 100 mg/day (n = 355) once daily," scientists writing in the Journal of Viral Hepatitis report. "ETV-022 had a 52-week blinded treatment phase, followed by an ...
2009 NOV 23 ... combined P = 9.25 x 10(-9), OR = 1.98, 95% CI = 1.57-2.52). IL28B contributes to viral resistance and is known to be upregulated by interferons and by RNA virus infection," ... "Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists ...
2009 NOV 23 ... testing, as well as open new avenues to decipher the mechanisms that underlie viral pathogenesis. The natural species tropism of HCV is, however, limited to humans and ... Data detailed in 'Towards a small animal model for hepatitis C' have been presented. "Hepatitis C virus (HCV) causes chronic liver disease and ...
2009 NOV 23 ... Carcinoma, Hepatology, Infectious Disease, Neoplasia, Oncology, Peroxidase, Reductase, Viral, Virology, Kaohsiung Medical University. This article was prepared by ... "To evaluate the redox status in hepatocellular carcinoma (HCC) induced by hepatitis B virus (HBV), the most important aetiological factor in Taiwan, changes in O-2(center ...
2009 NOV 23 ... published their study in Psychosomatics (Antiviral Completion Rates and Sustained Viral Response in Hepatitis C Patients With and Without Preexisting Major Depressive Disorder. ...
2009 NOV 23 ... Infectious Disease, Medical Device, Pancreas, Therapy, Treatment, Vaccination, Viral, Virology. This article was prepared by Biotech Business Week editors from ... to a study from Havana, Cuba, "CIGB-230, a mixture of a DNA plasmid expressing hepatitis C virus (HCV) structural antigens and a HCV recombinant capsid protein, has demonstrated ...
2009 NOV 16 ... 8% for 48 weeks [groups B and D]; RR, 2.00 [CI, 1.32 to 3.02]; P< 0.001). Complete viral suppression (HCV RNA level <50 IU/mL) at week 12 was achieved in 21% of patients in ... According to a study from the United States, "Many patients with chronic hepatitis C have not responded to therapy with pegylated interferon plus ribavirin. To evaluate ...
2009 NOV 16 ... "While many factors are implicated in determining the success rate for IFN therapy, viral genotype seems to play a crucial role. Examining differences in viral gene sequences has ... "Interferon-alpha (IFN-alpha) mono-therapy is largely ineffective for most of the hepatitis C virus (HCV)-infected patients that receive it. The addition of ribavirin to IFN ...
2009 NOV 16 ... and protease inhibitor. The results were significant antiviral potency and sustained viral reductions. In addition, the therapy appeared safe and well-tolerated. "The expected ... All approved therapy regimens to treat patients with hepatitis C are based on interferon, which must be injected. In this clinical trial to be ...
2009 NOV 16 ... HTLV, Hepatitis C Virus, Hepatology, Human T-Lymphotropic Virus, Infectious Disease, Viral Research, Virology, University of Sao Paulo, Medical Department. This ...
2009 NOV 16 ... with a 24-week post-treatment follow-up period. Consistent with previous reports, the viral response data continued to show comparable reductions in viral load for weight-based ... taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon, were presented at the American Association ...
2009 NOV 16 ... Interferon, Pharmaceutical Business, Pharmaceutical Company, Thrombin, Treatment, Viral Inhibition, Viral Therapy, Virology, ZymoGenetics Inc., ZymoGenetics Inc. ... as a single agent and with ribavirin in relapsed and treatment naive patients with hepatitis C. The results indicated that four week treatment with PEG-Interferon lambda and ...
